Fuzzy cluster analysis (FCA) was used to classify 166 outpatient positive treadmill stress tests as mildly, moderately, or severely abnormal. The method combines ST-segment change with five other stress test variables, and then computes a similarity measure to determine how closely each patient’s stress test resembles a prototypical mildly, moderately, or severely abnormal stress test. All patients had coronary angiography within 1 month of their stress tests. For the 45 patients with triple vessel disease (TVD), FCA classified 34 of these stress tests as severely abnormal (sensitivity = 75%). For the 22 patients with left main disease (LM), FCA classified 19 stress tests as severely abnormal (sensitivity = 86%). For the combined group with high-grade disease (TVD + LM), the sensitivity was 79%. A literature review shows that for stress echocardiography, multiple exercise-induced wall motion abnormalities have a sensitivity in the 70–80% range for patients with high-grade disease. For nuclear stress testing, the high-risk pattern of multiple reversible defects, with or without increased lung uptake, has a sensitivity in the range of 70–80% for patients with high-grade disease. Thus classification of a positive stress test as severely abnormal by FCA has a sensitivity comparable to high-risk patterns on stress echocardiography and nuclear stress testing in patients with TVD or LM.

Keywords:
Fuzzy cluster analysis, Stress test, Triple vessel disease, Left main coronary disease
1.
Peters R, Shanies S, Peers J: Fuzzy cluster analysis of positive stress tests, a method of combining exercise test variables to predict extent of coronary artery disease. Am J Cardiol 1995;76:648–651.
2.
Peters R, Shanies S, Peters J: Fuzzy cluster analysis, a new method to predict future cardiac events in patients with positive stress tests. Jpn Circ J 1998;62:750–754.
3.
Roger V, Pellikka P, Oh J, Bailey K, Tajik A: Identification of multivessel coronary artery disease by exercise echocardiography. J Am Coll Cardiol 1994;24:109–114.
4.
Crouse L, Harbrecht J, Vacek J, Rosamend T, Kramer P: Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary arteriography. Am J Cardiol 1991;67:1213–1218.
5.
Marwick T, Nemec J, Pashkow F: Accuracy and limitations of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol 1992;19:74–81.
6.
Armstrong W, O’Donnell J, Dillon J: Complementary value of two-dimensional exercise echocardiography to routine treadmill exercise testing. Ann Intern Med 1986;105:829–836.
7.
Rigo P, Bailey I, Griffith L: Value and limitation of segmental analysis of stress thallium myocardial imaging for localization of coronary artery disease. Circulation 1980;61:973–980.
8.
Wackers F, Soufer R, Zaret B: Nuclear cardiology; in Braunwald E (ed): Heart Disease. Philadelphia, Saunders, 1997, pp 279–311.
9.
Nygaard T, Gibson R, Ryan JM: Prevalence of high-risk thallium-201 scintigraphic findings in left main coronary artery stenosis: Comparison with patients with multiple and single-vessel coronary artery disease. Am J Cardiol 1984;53:462–469.
10.
Christian T, Miller T, Bailey K, Gibbons R: Noninvasive identification of severe coronary artery disease using exercise tomographic thallium-201 imaging. Am J Cardiol 1992;70:14–24.
11.
Froelicher V, Myers J, Follansbee W, Labovitz A: Exercise and the heart. St. Louis, Mosby, 1993, pp 136–284.
12.
Weiner DA, McCabe C, Ryan TJ: Identification of patients with left main and three vessel coronary disease with clinical and exercise test variables. Am J Cardiol 1980;46:21–27.
13.
Ribisl P, Morris CK, Kawaguchi T: Angiographic patterns and severe coronary artery disease. Arch Intern Med 1992;152:1618–1624.
14.
Taylor A, Sackett M, Beller GA: The degree of ST-segment depression on symptom-limited exercise testing: Relation to the myocardial ischemic burden as determined by thallium-201 scintigraphy. Am J Cardiol 1995;75:228–231.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.